|
Jared Ordway, Ph.D. is Director of Research and Development at Orion Genomics. Since joining Orion in 2004, he has participated in the development and validation of a novel comprehensive DNA methylation profiling technology and has applied this technology to the successful discovery of powerful DNA methylation-based biomarkers for various cancers. Dr. Ordway received his Ph.D. in Biochemistry and Molecular Genetics from the University of Alabama at Birmingham where his work was focused on the development and characterization of gene-targeted mouse models of neurodegenerative diseases caused by CAG repeat expansion mutations, including Huntington's Disease, Kennedy's Disease, and the spinocerebellar ataxias. He completed his Postdoctoral Fellowship in the laboratory of Dr. Tom Curran at St. Jude Children's Research Hospital where his research focused on the role of DNA methylation in oncogenic transformation and brain tumorigenesis. | 